Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 40Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Carcinoid Tumor 3Neoplasms 2Stomach Neoplasms 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Medulloblastoma 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1

Interventions

lutetium Lu 177 dotatate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × lutetium Lu 177 dotatate × Endocrine × Clear all
NCT04954820 2026-06-04

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡